Is SRPT or STOK more undervalued in 2026?

CirclFi compares Sarepta Therapeutics, Inc. (SRPT) and Stoke Therapeutics, Inc. (STOK) using 13 institutional-grade valuation models. SRPT has a Quality of Company score of 7.5/10 while STOK scores 6.2/10.

Which is a better buy — SRPT or STOK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SRPT and STOK valuations compare?

SRPT at $17.87 and STOK at $30.91 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SRPT vs STOK Valuation Comparison 2026 — Intrinsic Value Analysis

SRPT

Pharmaceutical Preparations

Sarepta Therapeutics, Inc.

Quality

7.5

out of 10

Value Trap

SAFE

Price

$17.87

Last close

Models

13/13

Active

STOK

Pharmaceutical Preparations

Stoke Therapeutics, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$30.91

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	SRPT Fair Value	SRPT Upside	STOK Fair Value	STOK Upside
Bayesian DCF	Intrinsic	$1.07	-94.0%	$11.28	-63.5%
Earnings Power Value	Intrinsic	$4.59	-77.4%	$6.33	-81.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SRPT vs STOK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SRPT vs STOK — Which Stock Is More Undervalued?

SRPT scores higher with a 7.5/10 quality rating vs STOK's 6.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sarepta Therapeutics, Inc. (SRPT) and Stoke Therapeutics, Inc. (STOK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SRPT currently trades at $17.87 with a QOC of 7.5/10, while STOK trades at $30.91 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).